Hormonal Regulation of Ocular Surface Health in Women

Abstract

The ocular surface demonstrates unique susceptibility to hormonal influences, particularly in women across various stages of life. This review synthesizes current evidence regarding the hormonal regulation of ocular surface health in women, with a focus on epidemiology, pathophysiology, clinical features, diagnostic approaches, and management strategies. Emphasis is placed on the roles of estrogen, progesterone, and androgens in maintaining ocular surface integrity, as well as on emerging therapies and guideline-based interventions. The goal is to provide clinicians and researchers with a comprehensive resource for understanding and addressing sex-specific factors in ocular surface disorders.

Introduction

The ocular surface, comprising the cornea, conjunctiva, lacrimal and meibomian glands, and tear film, is subject to complex regulatory mechanisms. Among these, hormonal modulation plays a critical role, with women showing a higher prevalence of dry eye disease and other ocular surface disorders. Fluctuations in sex hormones during puberty, menstruation, pregnancy, and menopause can acutely and chronically impact ocular surface health. Understanding these mechanisms is crucial for optimizing preventive and therapeutic strategies in women.

Epidemiology / Disease Burden

Epidemiological studies confirm that women are disproportionately affected by ocular surface diseases, especially dry eye syndrome, with prevalence rates up to twice those observed in men. The risk increases significantly after menopause and in women with underlying autoimmune conditions. The Women’s Health Study and other population-based cohorts have highlighted that hormonal transitions, such as menopause and use of hormone replacement therapy (HRT), influence both the incidence and severity of ocular surface pathology. This disease burden is associated with diminished quality of life and increased healthcare utilization among affected women.

Pathophysiology

Sex hormones, notably estrogen, progesterone, and androgens, exert pleiotropic effects on the ocular surface. Estrogen receptors (ERα and ERβ) and androgen receptors are expressed in ocular surface tissues and glands. Estrogen can promote inflammation and modulate mucin expression, while androgens support meibomian gland function and lipid layer homeostasis. Progesterone’s role is less well defined but appears to be immunomodulatory. Hormonal fluctuations can disrupt tear film stability, reduce goblet cell density, and promote meibomian gland dysfunction, culminating in increased tear evaporation and ocular surface inflammation.

Risk Factors

Hormonal status is a principal risk factor for ocular surface disease in women. Menopausal transition, pregnancy, use of oral contraceptives, and certain fertility treatments are associated with increased risk. Additional factors include autoimmune disease prevalence (e.g., Sjögren’s syndrome), thyroid dysfunction, and lifestyle factors such as contact lens use and environmental exposures. Genetic predisposition and ethnicity also modulate susceptibility, with some evidence suggesting a higher burden among Asian women.

Clinical Features

Common clinical manifestations include ocular discomfort, dryness, burning, foreign body sensation, photophobia, and fluctuating vision. Inflammatory changes may be evident with conjunctival hyperemia, punctate epithelial erosions, and decreased tear breakup time on examination. Chronic disease can lead to corneal epithelial compromise, recurrent infections, and, rarely, sight-threatening complications. Symptoms often fluctuate with hormonal cycles, pregnancy, or menopause, underscoring the need for a gender-sensitive clinical approach.

Diagnosis

Diagnosis relies on a combination of symptom assessment, clinical examination, and objective testing. Common tools include the Ocular Surface Disease Index (OSDI), Schirmer’s test, tear film breakup time (TBUT), and ocular surface staining with fluorescein or lissamine green. Meibography and tear osmolarity measurements can further delineate subtype and severity. Hormonal status, medication history, and systemic comorbidities should be carefully reviewed, as they may guide both diagnosis and management.

Treatment & Management

Management strategies are multifaceted and must be individualized. First-line therapies include artificial tears, lid hygiene, and environmental modifications. Topical anti-inflammatory agents (e.g., cyclosporine, lifitegrast) are indicated for persistent inflammation. For cases linked to androgen deficiency, topical androgen formulations are under investigation. Hormone replacement therapy has shown mixed results and is not routinely recommended solely for ocular surface disease. Addressing systemic risk factors and optimizing management of comorbidities such as thyroid or autoimmune disease are essential adjuncts.

Recent Advances / Emerging Therapies

Recent research has focused on the molecular pathways of hormone action at the ocular surface. Novel agents targeting specific inflammatory mediators and hormonal receptors are in development. Androgen-based therapies, selective estrogen receptor modulators (SERMs), and regenerative approaches such as stem cell therapy show promise. Advances in diagnostic imaging, such as high-resolution meibography and in vivo confocal microscopy, have enhanced early detection and personalized treatment planning. Ongoing clinical trials continue to investigate the safety and efficacy of hormone-modulating interventions in women with ocular surface disease.

Guideline Recommendations

Current clinical practice guidelines emphasize the importance of thorough history-taking, including hormonal status and systemic health, in women presenting with ocular surface complaints. Stepwise management escalating from lubricants to anti-inflammatory and immunomodulatory therapies is recommended. Hormone-based treatments should be considered only in select cases and under specialist supervision. Patient education and regular follow-up are central to effective disease control and prevention of complications.

Conclusion

Hormonal regulation is a pivotal factor in ocular surface health among women, influencing disease susceptibility, progression, and response to therapy. Clinicians should maintain a high index of suspicion for hormone-related ocular surface disorders and adopt a comprehensive, individualized approach to diagnosis and management. Ongoing research into hormone-targeted therapies and improved diagnostic modalities holds promise for optimizing care and outcomes in this population.